Ear nerve stimulation for lasting symptoms after Lyme disease treatment
Tests taVNS, a gentle ear device, in people with post-treatment Lyme disease symptoms.
Key facts
- Who runs it
- Columbia University
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- taVNS for Persistent Symptoms From Lyme Disease
- Status
- Recruiting
- People taking part
- 24 people, planned
- Started
- 8 May 2023
- Expected to end
- Dec 2026
- Type of study
- Interventional
- Treatments tested
- taVNS
- Record updated
- 6 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose symptoms have lasted after antibiotic treatment for Lyme disease. They will try an ear nerve stimulation device called taVNS.
- Age
- 18 Years to 65 Years
- Sex
- All sexes can join.
- Disease stage
- Definite or highly probable past Lyme disease, diagnosed and treated more than 6 months ago. At least one symptom has lasted since the first 6 months and causes real distress or limits daily life. Moderate to severe tiredness is needed, a score of 4 or more on the Fatigue Severity Scale (FSS).
- Earlier treatment
- At least two courses of antibiotics for Lyme disease. Current treatments must have been stable for at least 6 weeks. No antibiotics for tick-borne illness in the last 6 weeks.
Main reasons for not taking part
- Heart or blood vessel disease, unexplained fainting in the last year, slow heart rate with symptoms, or low blood pressure; abnormal EKG
- Major brain or nerve disease, brain surgery or brain tumour
- Moderate-severe or severe depression, recent suicidal thoughts with a plan, or past suicidal behaviour
- Taking opiate-based medicine; ear pain, infection, damage or cochlear implants
- Being pregnant or planning pregnancy; pacemakers or other electrical devices, or metal implants above the neck
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- History of either Definite or Highly Probable Past Lyme disease diagnosed and treated by a health care provider more than 6 months previously
- Have one or more current symptoms attributed to Lyme disease that were also present during the initial 6-month period after diagnosis and antibiotic treatment of Lyme disease
- Individuals reporting that current symptoms cause clinically significant distress or impairment in functioning
- Previously treated for Lyme disease with at least two courses of antibiotics considered appropriate for Lyme disease
- Individuals who agree to not start a new medical or psychiatric treatment (that might impact study outcomes) for their chronic symptoms during the course of this study (unless deemed necessary by their primary care physician (PCP))
- Individuals whose current treatment (that might impact study outcomes) has been stable for at least 6 weeks prior to baseline visit
- Lives in the U.S. and owns a smartphone, tablet or computer with Internet access
- Able to read and understand English to be able to provide informed consent
- Able and willing to come to Columbia University Irving Medical Center in NYC for 3-5 study visits
- Willingness to have a 12-lead electrocardiogram (EKG) when evaluated on site and, if an EKG was conducted in the past year, willingness to try to obtain that EKG for us to review
- Current moderate to severe fatigue. At least moderate intensity at study screening (a score of 4 or more on the Fatigue Severity Scale (FSS))
- Ability to allocate sufficient time for the treatment sessions, including 6 sessions that will be monitored during work hours (8 am to 6 pm)
Who cannot take part
- Currently taking opiate-based medication or have taken antibiotics in the last 6 weeks for tick-borne illness
- Individuals who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
- Current or past history of cardiovascular disorder(s) (coronary artery disease, peripheral artery disease, stroke, aortic disease, or other major cardiac condition). A history within the last year of unexplained fainting spells or of vasovagal syncope or feeling faint in response to medical settings or pain. Symptomatic bradycardia, orthostatic (postural) hypotension not correctable by fluid intake (i.e., a drop of >20 mm Hg systolic, 10 mm Hg diastolic or both), or persistent hypotension (BP below 90 mmHg systolic)
- A diagnosed current major central nervous system disease (e.g., multiple sclerosis (MS), epilepsy, neurodegenerative diseases, ischemic stroke, Parkinson's, traumatic brain injury with cognitive impairment, etc.) or a history of brain surgery or brain tumors
- A current psychiatric disorder that might impact treatment compliance (e.g., bipolar disorder, psychosis, substance abuse)
- Suicidal ideation with method, plan or intent in the last 6 months or a lifetime history of suicidal behavior
- Current serious unstable medical illness
- Ear-related: a) facial or ear pain; b) recent ear trauma; c) damage to left or right ear or anatomy that does not allow taVNS; d) ear infection (otitis media or externa); e) scar or inflammation on ear; f) Cochlear implants
- Individuals with an active external or implanted electrical medical device (e.g., cardiac pacemaker, hearing aid implant) or any metal implant above the level of the neck
- Abnormal EKG findings (e.g., significant bradycardia) considered significant by a cardiologist
- Current moderate-severe or severe depression (T-score of 65 or higher on the PROMIS-Emotional Distress-Depression SF) at screening
- Currently or recently (within 6 months) in a clinical trial of an investigational medicinal product or another medical device
- Females who are pregnant or planning to become pregnant during the course of this study
- Unable to connect to the Internet during treatment phase
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Lyme and Tick-Borne Diseases Research CenterNew York, United StatesContact: Brian A. Fallon, MDTaking people
About the trial
What the trial wants to find out
This study is one of the first studies to investigate a non-antibiotic approach to the treatment of symptoms that persist after antibiotic treatment for Lyme disease (PTLS). Transcutaneous auricular vagus nerve stimulation (taVNS) offers the potential of being an effective and non-toxic approach to reduce the burden of multisystem symptoms in patients with PTLS. This study seeks to address an important goal: to assess the safety, feasibility, and tolerability of a new non-invasive, non-pharmacologic treatment for patients with symptoms that persist despite prior antibiotic treatment for Lyme disease.
The group in the trial
- PTLD - active taVNSTreatment being tested
Participants with Post-treatment Lyme Disease (PTLD) will start with 40 sessions (i.e., 4 weeks of Monday to Friday, twice daily treatments that last 1 hour each session) to receive transcutaneous auricular Vagus Nerve Stimulation (taVNS). If compliance is less than 70% in the open label treated participants, then the investigators will modify the treatment design accordingly.
Treatment: taVNS
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Persistent Symptoms From Lyme Disease: a Feasibility, Tolerability, and Safety Study
- Plain-language title
- Ear nerve stimulation for lasting symptoms after Lyme disease treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT05776251, who can take part
- Record updated
- 6 May 2026